Hepatic arterial infusion chemotherapy with gemcitabine and 5‑fluorouracil or oral S‑1 improves the prognosis of patients with postoperative liver metastases from pancreatic cancer

International Agency for Research on Cancer, World Health Organization. Globocan 2008. World Health Organization. Website. http://globocan.iarc.fr/. Accessed October 1, 2010

Ishii H, Furuse J, Boku N, et al: Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol. 40:573–579. 2010. View Article : Google Scholar : PubMed/NCBI

Evans DB, Abbruzzese JL and Willett CG: Cancer of the pancreas. Cancer: Principles and Practice of Oncology. De Vita VT, Hellman S and Rosenberg SA: 6th edition. Lippincott Williams and Wilkins; Philadelphia: pp. 1126–1161. 2001

Oettle H, Post S, Neuhaus P, et al: Adjuvant chemotherapy with gemcitabine vs. observation in patients undergo curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 297:267–277. 2007. View Article : Google Scholar : PubMed/NCBI

Aloia TA, Lee JE, Vauthey JN, et al: Delayed recovery after pancreaticoduodenectomy: a major factor impairing the delivery of adjuvant chemotherapy? J Am Coll Surg. 204:347–355. 2007. View Article : Google Scholar : PubMed/NCBI

Sandy H, Bruckner H, Cooperman A, Paradiso J and Kiefer L: Survival advantage of combined chemoradiotherapy compared with resection as the initial treatment of patients with regional pancreatic carcinoma. An outcomes trial. Cancer. 89:314–327. 2000. View Article : Google Scholar

Ensminger WD, Rosowsky A and Raso V: A clinical pharmacological evaluation of hepatic arterial infusions of 5-fluoro-2-deoxyuridine and 5-fluoroufacil. Cancer Res. 38:3784–3792. 1978.PubMed/NCBI

Vogl TJ, Schwarz W, Eichler K, et al: Hepatic intraarterial chemotherapy with gemcitabine in patients with unresectable cholangiocarcinoma and liver metastases of pancreatic cancer: a clinical study on maximum tolerable dose and treatment efficacy. J Cancer Res Clin Oncol. 132:745–755. 2006. View Article : Google Scholar

Tse AN, Wu N, Patel D, Haviland D and Kemeny N: A phase I study of gemcitabine given via intrahepatic pump for primary or metastatic hepatic malignancies. Cancer Chemother Pharmacol. 64:935–944. 2009. View Article : Google Scholar : PubMed/NCBI

Van Riel JM, Peters GJ, Mammatas LH, et al: A phase I and pharmacokinetic study of gemcitabine given by 24-h hepatic arterial infusion. Eur J Cancer. 45:2519–2527. 2009.PubMed/NCBI

Tajima H, Ohta T, Kitagawa H, et al: Pilot study of hepatic arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for patients with postoperative liver metastases from pancreatic cancer. Exp Therap Med. 2:265–269. 2011. View Article : Google Scholar

Nakamura K, Yamaguchi T, Ishihara T, et al: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 92:2134–2139. 2005. View Article : Google Scholar : PubMed/NCBI

Ueno H, Okusaka T, Ikeda M, et al: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology. 69:421–427. 2005. View Article : Google Scholar : PubMed/NCBI

Nakamura K, Yamaguchi T, Ishihara T, et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer. 94:1575–1579. 2006.PubMed/NCBI

Ueno H, Ioka T, Ikeda M, et al: Randomized phase III study of gemcitabine plus S-1 (GS) versus S-1 alone, or gemcitabine alone in patiens with locally advanced and metastatic pancreatic cacer in Japan and Taiwan: GEST study. J Clin Oncol. 31:1640–1648. 2013. View Article : Google Scholar : PubMed/NCBI

Urata K, Kawasaki S, Matsunami T, et al: Calculation of child and adult standard liver volume for liver transplantation. Hepatology. 21:1317–1321. 1995.PubMed/NCBI

Tajima H, Ohta T, Kitagawa H, et al: Hepatic arterial infusion chemotherapy for post-operative liver metastases from pancreatic cancer in a patient with leukocytopenia: a case report. Exp Therap Med. 1:987–990. 2010.PubMed/NCBI

Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000. View Article : Google Scholar : PubMed/NCBI

Nagakawa T, Nagamori M, Futakami F, et al: Result of extensive surgery for pancreatic carcinoma. Cancer. 77:640–645. 1996. View Article : Google Scholar : PubMed/NCBI

Noto M, Miwa K, Kitagawa H, et al: Pancreas head carcinoma: frequency of invasion to soft tissue adherent to the superior mesenteric artery. Am J Surg Pathol. 29:1056–1061. 2005.PubMed/NCBI

Homma H, Akiyama T, Mezawa S, et al: Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy. Int J Clin Oncol. 9:197–201. 2004. View Article : Google Scholar : PubMed/NCBI

Miyanishi K, Ishiwatari H, Hayashi T, et al: A Phase I trial of arterial infusion chemotherapy with gemcitabine and 5-fluorouracil for unresectable advanced pancreatic cancer after vascular supply distribution via superselective embolization. Jpn J Clin Oncol. 38:268–274. 2008. View Article : Google Scholar

Kikuchi K and Kanno H: Comparison for blood levels and clinical effects between tablet and other dosage forms of 5-fluorouracil (5-FU). Gan To Kagaku Ryoho. 6:559–565. 1979.(In Japanese).

Maruyama S, Ando M and Watayo T: Concentration of 5-FU after hepatic artery infusion chemotherapy for liver metastases of colorectal cancer. Gan To Kagaku Ryoho. 30:1635–1638. 2003.(In Japanese).

Tajima H, Kitagawa H, Tsukada T, et al: A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer. Mol Clin Oncol. 1:768–772. 2013.PubMed/NCBI

Nakahira S, Nakamori S, Tsujie M, et al: Pretratment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effect in pancreatic cancer xenografts. Anticancer Res. 28:179–186. 2008.PubMed/NCBI